Ha habido 50 transacciones internas recientes registradas para POINT Biopharma Global Inc. (PNT), incluyendo 25 compras y 21 ventas. El total de compras internas fue valorado en $14.9M y el total de ventas internas en $70.58M.
Internos destacados con actividad reciente incluyen Silber Allan C, Lubner David Charles, Malik Rajesh. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — PNT
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2023-12-27 |
Silber Allan C |
Executive Chairman |
Devolución de Acciones |
537,322 |
$6.78 |
$3.64M |
- |
| 2023-12-27 |
Lubner David Charles |
Director |
Devolución de Acciones |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Malik Rajesh |
Director |
Devolución de Acciones |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Fleshner Neil E. |
Chief Medical Officer |
Devolución de Acciones |
84,257 |
$6.78 |
$571.26K |
- |
| 2023-12-27 |
Demers William L. |
Chief Financial Officer |
Devolución de Acciones |
131,355 |
$6.78 |
$890.59K |
- |
| 2023-12-27 |
Goodman Jonathan R. |
Director |
Devolución de Acciones |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Margolin Yael |
Director |
Devolución de Acciones |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Mccann Joe A. |
Chief Executive Officer |
Devolución de Acciones |
692,643 |
$6.78 |
$4.7M |
- |
| 2023-12-27 |
Hogue Gerald L. |
Director |
Devolución de Acciones |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Jensen Jessica D. |
EVP Clinical Development |
Devolución de Acciones |
136,055 |
$6.78 |
$922.45K |
- |
| 2023-12-27 |
Kelly Justyna |
Chief Operating Officer |
Devolución de Acciones |
98,358 |
$6.78 |
$666.87K |
- |
| 2023-12-26 |
Lubner David Charles |
Director |
OPA (Venta) |
35,400 |
$12.50 |
$442.5K |
3,600 |
| 2023-12-26 |
Malik Rajesh |
Director |
OPA (Venta) |
3,700 |
$12.50 |
$46.25K |
- |
| 2023-12-26 |
Goodman Jonathan R. |
Director |
OPA (Venta) |
41,872 |
$12.50 |
$523.4K |
- |
| 2023-12-26 |
Hogue Gerald L. |
Director |
OPA (Venta) |
21,596 |
$12.50 |
$269.95K |
- |
| 2023-12-22 |
Silber Allan C |
Executive Chairman |
OPA (Venta) |
71,744 |
$12.50 |
$896.8K |
- |
| 2023-12-22 |
Fleshner Neil E. |
Chief Medical Officer |
OPA (Venta) |
358 |
$12.50 |
$4.48K |
- |
| 2023-12-22 |
Mccann Joe A. |
Chief Executive Officer |
OPA (Venta) |
3,494,153 |
$12.50 |
$43.68M |
- |
| 2023-12-18 |
Bvf Partners L P/il |
Officer |
Venta Informativa |
896,366 |
$12.45 |
$11.16M |
- |
| 2023-11-06 |
Mccann Joe A. |
Chief Executive Officer |
Donación (Otorgada) |
120,000 |
- |
- |
3,494,153 |
| 2023-11-03 |
Silber Allan C |
Executive Chairman |
Donación (Otorgada) |
500,000 |
- |
- |
38,087 |
| 2023-11-02 |
Bvf Partners L P/il |
10 Percent Owner |
Disposición |
- |
- |
- |
896,366 |
| 2023-10-31 |
Fleshner Neil E. |
Chief Medical Officer |
Donación (Otorgada) |
250,000 |
- |
- |
2,773,045 |
| 2023-06-13 |
Martell Bridget A |
Director |
Concesión de RSU |
80,503 |
$10.08 |
$811.47K |
80,503 |
| 2023-06-12 |
Martell Bridget A |
Director |
Desconocido |
- |
- |
- |
- |
| 2023-06-01 |
Lubner David Charles |
Director |
Concesión de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Malik Rajesh |
Director |
Concesión de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Goodman Jonathan R. |
Director |
Concesión de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Margolin Yael |
Director |
Concesión de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Hogue Gerald L. |
Director |
Concesión de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-03-28 |
Silber Allan C |
10 Percent Owner, Officer: Executive Chairman |
Concesión de RSU |
537,322 |
$6.78 |
$3.64M |
537,322 |
| 2023-03-28 |
Fleshner Neil E. |
Chief Medical Officer |
Concesión de RSU |
84,257 |
$6.78 |
$571.26K |
84,257 |
| 2023-03-28 |
Demers William L. |
Chief Financial Officer |
Concesión de RSU |
131,355 |
$6.78 |
$890.59K |
131,355 |
| 2023-03-28 |
Mccann Joe A. |
Chief Executive Officer |
Concesión de RSU |
692,643 |
$6.78 |
$4.7M |
692,643 |
| 2023-03-28 |
Jensen Jessica D. |
EVP Clinical Development |
Concesión de RSU |
136,055 |
$6.78 |
$922.45K |
136,055 |
| 2023-03-28 |
Kelly Justyna |
Chief Operating Officer |
Concesión de RSU |
98,358 |
$6.78 |
$666.87K |
98,358 |
| 2023-03-21 |
Hogue Gerald L. |
Director |
Ejercicio de Opciones (Venta) |
17,936 |
$6.97 |
$125.01K |
17,936 |
| 2022-11-29 |
Mccann Joe A. |
Chief Executive Officer |
Compra Informativa |
2,160 |
$6.64 |
$14.34K |
3,616,313 |
| 2022-11-28 |
Malik Rajesh |
Director |
Compra Informativa |
3,700 |
$6.66 |
$24.64K |
3,700 |
| 2022-11-25 |
Hogue Gerald L. |
Director |
Compra Informativa |
3,660 |
$6.82 |
$24.94K |
3,660 |
| 2022-11-23 |
Lubner David Charles |
Director |
Compra Informativa |
3,600 |
$6.85 |
$24.66K |
3,600 |
| 2022-11-21 |
Margolin Yael |
Director |
Compra Informativa |
1,710 |
$6.56 |
$11.22K |
1,710 |
| 2022-11-18 |
Silber Allan C |
Executive Chairman |
Compra Informativa |
22,397 |
$6.50 |
$145.58K |
4,268,605 |
| 2022-11-18 |
Goodman Jonathan R. |
Director |
Compra Informativa |
6,000 |
$6.33 |
$37.98K |
41,872 |
| 2022-11-17 |
Silber Allan C |
Executive Chairman |
Compra Informativa |
27,603 |
$6.00 |
$165.62K |
4,246,208 |
| 2022-06-02 |
Lubner David Charles |
Director |
Concesión de RSU |
25,614 |
$8.31 |
$212.85K |
25,614 |
| 2022-06-02 |
Malik Rajesh |
Director |
Concesión de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Goodman Jonathan R. |
Director |
Concesión de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Margolin Yael |
Director |
Concesión de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Hogue Gerald L. |
Director |
Concesión de RSU |
25,614 |
- |
- |
25,614 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
